Clinical Trials Logo

Kidney Failure, Chronic clinical trials

View clinical trials related to Kidney Failure, Chronic.

Filter by:

NCT ID: NCT00150319 Terminated - Kidney Failure Clinical Trials

An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

Start date: June 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to investigate the pharmacokinetics, safety and tolerability of intravenous voriconazole and SBECD in patients with moderate renal insufficiency

NCT ID: NCT00144118 Terminated - Kidney Failure Clinical Trials

The Effect of Isoflurane or Sevoflurane on Kidney Function

Start date: January 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if isoflurane and sevoflurane have similar effects on the kidneys of people with impaired kidneys when the drugs administered with low gas flow into anaesthetic machines.

NCT ID: NCT00108485 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

Start date: April 2005
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to test the effectiveness and tolerability of Niaspan® to improve the levels of blood fats ("good" and "bad" cholesterol and triglyceride levels) in people who have kidney damage due to diabetes. A secondary goal is to test whether Niaspan® slows down further development of kidney damage.

NCT ID: NCT00090194 Terminated - Clinical trials for Kidney Failure, Chronic

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

Start date: June 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if IGIV-C, 10% will be effective in converting a donor-recipient crossmatch status from positive to negative. The crossmatch test is used to determine if the donor tissue and recipient tissue are compatible. The study will also evaluate if IGIV-C, 10% will allow successful kidney transplantation in a patient who otherwise would not be able to receive a transplant. Three dose levels of IGIV-C, 10% will be evaluated to determine what dose level is most effective.